Boston Trust Walden Corp Cuts Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Boston Trust Walden Corp decreased its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 35.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 584,800 shares of the biotechnology company's stock after selling 314,261 shares during the period. Boston Trust Walden Corp owned 0.55% of Corcept Therapeutics worth $66,796,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. CWA Asset Management Group LLC raised its position in Corcept Therapeutics by 21.6% during the 1st quarter. CWA Asset Management Group LLC now owns 19,802 shares of the biotechnology company's stock valued at $2,262,000 after purchasing an additional 3,511 shares during the last quarter. QRG Capital Management Inc. raised its position in Corcept Therapeutics by 0.6% during the 1st quarter. QRG Capital Management Inc. now owns 96,923 shares of the biotechnology company's stock valued at $11,071,000 after purchasing an additional 558 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Corcept Therapeutics by 3.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 7,954 shares of the biotechnology company's stock valued at $909,000 after purchasing an additional 230 shares during the last quarter. Goldstone Financial Group LLC bought a new position in Corcept Therapeutics during the 1st quarter valued at approximately $547,000. Finally, SG Americas Securities LLC raised its position in Corcept Therapeutics by 285.3% during the 1st quarter. SG Americas Securities LLC now owns 43,109 shares of the biotechnology company's stock valued at $4,924,000 after purchasing an additional 31,922 shares during the last quarter. Institutional investors own 93.61% of the company's stock.

Corcept Therapeutics Stock Up 0.2%

Shares of NASDAQ:CORT traded up $0.14 during trading on Friday, hitting $71.38. The stock had a trading volume of 1,735,082 shares, compared to its average volume of 1,135,919. Corcept Therapeutics Incorporated has a 12 month low of $29.42 and a 12 month high of $117.33. The company has a market capitalization of $7.57 billion, a PE ratio of 61.53 and a beta of 0.19. The firm's fifty day moving average is $71.56 and its 200 day moving average is $64.76.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.17 earnings per share for the quarter, meeting analysts' consensus estimates of $0.17. Corcept Therapeutics had a return on equity of 20.40% and a net margin of 19.33%. The company had revenue of $157.21 million during the quarter, compared to analyst estimates of $177.93 million. During the same quarter last year, the company earned $0.25 EPS. The firm's revenue for the quarter was up 7.1% on a year-over-year basis. Equities research analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Insider Activity at Corcept Therapeutics

In related news, insider Sean Maduck sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $100.54, for a total transaction of $10,054,000.00. Following the completion of the transaction, the insider now owns 85,622 shares of the company's stock, valued at $8,608,435.88. This trade represents a 53.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joseph Douglas Lyon sold 421 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $60.58, for a total value of $25,504.18. Following the transaction, the insider now directly owns 9,009 shares of the company's stock, valued at approximately $545,765.22. This trade represents a 4.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 362,325 shares of company stock valued at $30,509,238 in the last 90 days. Corporate insiders own 20.80% of the company's stock.

Analyst Ratings Changes

CORT has been the subject of a number of recent analyst reports. Truist Financial set a $135.00 price target on Corcept Therapeutics in a research report on Tuesday, May 6th. Canaccord Genuity Group increased their target price on Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Piper Sandler increased their target price on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a research report on Thursday, April 3rd. Wall Street Zen lowered Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Finally, HC Wainwright decreased their target price on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Corcept Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $138.25.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.